Pharmaceutical Market Changes: EU and USA Update Regulatory and Pricing Frameworks

In late December 2025, distinct regulatory and commercial developments regarding the pharmaceutical industry were announced in the European Union (hereinafter: EU) and the United States of America (hereinafter: USA). European lawmakers finalised a provisional agreement to revise the legislative framework governing medicines, while the government in Washington secured voluntary pricing agreements with several major pharmaceutical manufacturers.

Regulatory Adjustments in the European Union

On 11 December 2025, the Council and the European Parliament reached a provisional agreement on a new set of rules for the pharmaceutical sector. This legislation represents the first significant update to the pharmaceutical laws of the bloc since 2004. The stated objectives of the reform are to improve access to affordable medicines and address unmet medical needs.

The agreement establishes a new baseline for regulatory data protection. Under the revised terms, manufacturers will receive eight years of data protection followed by one year of market exclusivity, during which generic or biosimilar products cannot be sold. This structure replaces the previous system, modifying the duration of protection available to companies. The framework allows for extensions to these periods — up to a capped maximum of 11 years — if specific conditions are met, such as the development of medicines for rare diseases or the conduct of comparative clinical trials across multiple member states.

Additionally, the legislation introduces a “transferable exclusivity voucher” to incentivise the development of new antibiotics. This mechanism permits a company to extend data protection on a different product for 12 months, provided the product does not generate annual gross sales exceeding 490€ million. The agreement also updates the “Bolar exemption”, enabling generic manufacturers to conduct studies and prepare regulatory files during the patent protection period of an original medicine.

Pricing Agreements in the United States of America

Concurrent with European legislative updates, the government of the USA announced a series of agreements with pharmaceutical companies aimed at reducing the cost of prescription drugs. On 19 December 2025, the President confirmed that 14 pharmaceutical companies had agreed to terms intended to align prices in the domestic market with those in other developed nations.

The companies involved, which include Amgen, Bristol Myers Squibb, GSK, Merck and Pfizer, have committed to a “most-favoured-nation” pricing model. To facilitate distribution under these terms, the government plans to launch a direct purchasing platform titled “TrumpRx.gov”. Specific price reductions were outlined for certain medications; for example, Merck is set to offer diabetes drugs at approximately 70% below list prices, while Amgen will provide specific treatments for migraine and rheumatoid arthritis at reduced rates.

In conjunction with these pricing adjustments, the participating manufacturers pledged to invest a collective 150$ billion in domestic manufacturing and research and development. The agreements also include provisions for companies to donate active pharmaceutical ingredients to a strategic reserve. In return for these commitments, the administration offered tariff exemptions for a period of three years.

Industry Perspectives

Responses to these developments have varied. In Europe, the European Federation of Pharmaceutical Industries and Associations noted that the reduction in baseline data protection might impact the region’s ability to attract investment, stating: “If this is the legislative framework that is expected to attract the medicines innovation of the next 20 years to Europe, the outcome of the trialogues is underwhelming”. Conversely, in the USA, officials indicated that the new deals would result in “massive savings” for government programmes, though analysts noted that Medicaid already receives significant discounts.

Concluding Outlook

The developments in the European Union and the USA reflect different methods of engaging with the pharmaceutical industry. The EU has focused on modifying the statutory duration of data protection and market exclusivity to influence market dynamics, whereas the United States of America have pursued direct commercial negotiations combined with trade incentives. These distinct approaches establish separate operating environments for pharmaceutical entities in two of the largest global markets, potentially influencing future corporate strategies regarding regional investment and product launches.

With the measures, the stocks of the pharmaceutical companies in the USA have surged in the past weeks, signalling that the measures have already attracted capital in the negotiation phases of the deal. Accordingly, it is expected that the companies will further consolidate their market positions with more confident support by the government.